Teva 'Plagued By Problems,' Downgraded On Lost MS Drug Patents, DOJ Probe | Stock News & Stock Market Analysis - IBD
Teva launches Copaxone with the YpsoMate autoinjector from Ypsomed - Ypsomed - Canada
Swedish Biotech Faces Another Phase III Flop in Multiple Sclerosis
3rd Oral Drug to Treat MS Is Approved by the F.D.A. - The New York Times
Feds accuse Teva of $300M in kickbacks for MS drug - Drug Discovery and Development
Teva loses key MS drug patent | Nature Reviews Drug Discovery
Teva steps up defence of key MS drug
Teva Is the 23rd Drug Maker to Impose Limits on 340B Contract Pharmacies - 340B Report
Teva and BioGen Locked in Dispute Over MS Drug Agreement | New Jersey Law Journal
Multiple Sclerosis Drugs Market Size, Growth | Forecast 2027
Teva shares rise in Tel Aviv as migraine results buoy investors | The Times of Israel
Drug Maker Teva to Pay Over $500 Million in New York Drug Case Settlement - The New York Times
Teva knocked as competition fears grow for MS drug
What are the implications of a generic Teva MS drug? Here's what the wags say - STAT
World MS Day, May 31, Marked by Teva's 'Life Moments with MS' Social Media Campaign
U.S. court ruling on MS drug is the latest blow for Teva | Reuters
Teva and Active Biotech Expand Investigational MS Treatment Program
Federal Judge, Clarifying FCA Causation, Grants Feds Partial Summary Judgment | Law.com
Multiple Sclerosis Drugs Market Size, Share | CAGR of 3.8%
US regulator backs copycat version of Teva MS drug
PTAB invalidates three patents covering Teva's Copaxone, opens door for Mylan's generic version - IPWatchdog.com | Patents & Intellectual Property Law
Teva names new CFO and bulks up its opioid liability fund - PMLiVE
